Single oncogenic driver of glioblastoma: The SRSF3 splicing factor.

Takeaway

  • SRSF3 was directly associated with the development, progression and aggressiveness of glioblastoma and also correlated with patient survival. This gene represents a novel therapeutic target that warrants clinical testing.

Why this matters

  • There is emerging data that indicate gene splicing mechanisms are altered in tumors, which lead to oncogenic splicing events associated with the progression and aggressiveness of tumors.

  • The results from this study provide valuable insights of the splicing machinery in glioblastomas and to developing novel strategies to support the diagnosis, prognosis and treatment of glioblastomas.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.